BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

07 فبراير 2024 06:34:22 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 فبراير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05 فبراير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

02 فبراير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

18 يناير 2024 06:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

10 يناير 2024 16:15:42 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 يناير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

03 يناير 2024 15:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

03 يناير 2024 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

13 ديسمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 ديسمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05 ديسمبر 2023 06:45:07 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

09 نوفمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08 نوفمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

02 نوفمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

10 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

09 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

03 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

25 سبتمبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire